Translating nutritional immunology into drug development for inflammatory bowel disease

Curr Opin Gastroenterol. 2016 Nov;32(6):443-449. doi: 10.1097/MOG.0000000000000317.

Abstract

Purpose of review: To highlight recent advances in the understanding of nutritional immunology and in the development of novel therapeutics for inflammatory bowel disease (IBD).

Recent findings: We highlight the variety of factors that contribute to the interaction of the immune system and nutrition including the microbiome and the nervous system stimulation of the gut. We describe the potential for therapeutic development in IBD. Further, we review the cellular metabolic effects on immune activation and promising therapeutic targets. Finally, we show how the progression of understanding the role of lanthionine synthetase C-like 2 has encompassed both nutritional and therapeutic advances and led to the development of novel oral small molecule therapeutics for IBD.

Summary: Nutritional immunology and drug development research centered around immunoregulatory pathways can provide safer and more effective drugs while accelerating the path to cures.

Publication types

  • Review

MeSH terms

  • Drug Discovery / methods*
  • Gastrointestinal Agents / therapeutic use
  • Gastrointestinal Microbiome
  • Humans
  • Inflammatory Bowel Diseases / drug therapy*
  • Inflammatory Bowel Diseases / immunology*
  • Inflammatory Bowel Diseases / microbiology
  • Molecular Targeted Therapy / methods
  • Nutritional Physiological Phenomena / immunology*
  • Translational Research, Biomedical / methods

Substances

  • Gastrointestinal Agents